English

Insider transactions

EDGAR

Enveric Biosciences, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-15.

Open-market purchases (code P): 0 transactions, — shares
Open-market sales (code S): 0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–7 of 7

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
Date	Reporting owner	Code	Acquired or disposed	Shares	Value (derived)	Shares owned after	Direct or indirect	Rule 10b5-1 box	Notes	Source
2025-12-23 Filed 2025-12-30	Kegler George A. Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	7,633	—	7,900	Direct (D)	No	F1, F2 F1 Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the Plan). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement. F2 On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the January Reverse Stock Split). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (theOctober Reverse Stock Split together with the January Reverse Stock Split, the Reverse Stock Splits). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.	Open filing 0001193125-25-337182 Read from the filing’s XML Dispute this row
2025-12-23 Filed 2025-12-30	DeWitt Sheila Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	7,633	—	7,788	Direct (D)	No	F1, F2 F1 Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the Plan). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement. F2 On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the January Reverse Stock Split). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (theOctober Reverse Stock Split together with the January Reverse Stock Split, the Reverse Stock Splits). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.	Open filing 0001193125-25-337184 Read from the filing’s XML Dispute this row
2025-12-23 Filed 2025-12-30	Coveney Kevin Michael Officer: Chief Financial Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	40,198	—	47,413	Direct (D)	No	F1, F2 F1 Represents the restricted stock units (the RSUs) granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the Company) 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company. F2 On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the Reverse Stock Split). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.	Open filing 0001193125-25-337171 Read from the filing’s XML Dispute this row
2025-12-23 Filed 2025-12-30	WEBB MICHAEL D Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	7,633	—	7,898	Direct (D)	No	F1, F2 F1 Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the Plan). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement. F2 On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the January Reverse Stock Split). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (theOctober Reverse Stock Split together with the January Reverse Stock Split, the Reverse Stock Splits). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.	Open filing 0001193125-25-337172 Read from the filing’s XML Dispute this row
2025-12-23 Filed 2025-12-30	PASQUALONE FRANK Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	7,633	—	7,904	Direct (D)	No	F1, F2 F1 Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the Plan). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement. F2 On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the January Reverse Stock Split). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (theOctober Reverse Stock Split together with the January Reverse Stock Split, the Reverse Stock Splits). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.	Open filing 0001193125-25-337179 Read from the filing’s XML Dispute this row
2025-12-23 Filed 2025-12-30	Tucker Joseph Edward Director · Officer: Chief Executive Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	60,296	—	70,355	Direct (D)	No	F1, F2 F1 Represents the restricted stock units (the RSUs) granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the Company) 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company. F2 On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the Reverse Stock Split). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.	Open filing 0001193125-25-337175 Read from the filing’s XML Dispute this row
2025-12-23 Filed 2025-12-30	Schabacker Marcus Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	7,633	—	7,900	Direct (D)	No	F1, F2 F1 Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the Plan). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement. F2 On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the January Reverse Stock Split). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (theOctober Reverse Stock Split together with the January Reverse Stock Split, the Reverse Stock Splits). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.	Open filing 0001193125-25-337178 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 2,285 filings read, the latest filed 2026-11-12. Prior quarter ending 2026-06-30: 16 filings read.

Showing 1–7 of 7

Institutional holders, largest position first, as filed
Manager	Shares or principal	Value as filed	Change from the prior quarter	Source
AdvisorShares Investments LLC	43,783 SH	64,361 dollars	Prior quarter not fully read: no change stated	Open filing 0001829126-26-012138 Filed 2026-11-09 Dispute this row
JANE STREET GROUP, LLC Partly reported under another manager	19,444 SH	28,874 dollars	Prior quarter not fully read: no change stated	Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
Arax Advisory Partners Partly reported under another manager	8 SH	12 dollars	Prior quarter not fully read: no change stated	Open filing 0001586767-26-000009 Filed 2026-11-12 Dispute this row
FMR LLC Partly reported under another manager	2 SH	3 dollars	Prior quarter not fully read: no change stated	Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
CITIGROUP INC Partly reported under another manager	1 SH	1 dollars	Prior quarter not fully read: no change stated	Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
DANSKE BANK A/S	1 SH	1 dollars	Prior quarter not fully read: no change stated	Open filing 0001104659-26-124081 Filed 2026-11-09 Dispute this row
OSAIC HOLDINGS, INC. Partly reported under another manager	1 SH	1 dollars	Prior quarter not fully read: no change stated	Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row

Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
A change is the difference between two quarter-end snapshots, not a trade.
A position reported under another manager may also appear in that manager’s filing; rows are not added together.
Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
Holder	Percent of class	Shares held	Event date	Form	Source
Sio Capital Management, LLC Common Stock, par value, $0.01 per share	7.37	330,000.00	09/30/2026 Filed 2026-11-03	SCHEDULE 13G	Open filing 0001214659-26-013680 Dispute this row
Armistice Capital, LLC Common stock, par value $0.01 per share	9.99	405,092.00	06/30/2026 Filed 2026-08-14	SCHEDULE 13G	Open filing 0001172661-26-003572 Dispute this row
Steven Boyd Common stock, par value $0.01 per share	9.99	405,092.00	06/30/2026 Filed 2026-08-14	SCHEDULE 13G	Open filing 0001172661-26-003572 Dispute this row
Lind Global Fund III LP Common Stock, $0.01 par value	1.3	49,366	06/30/2026 Filed 2026-08-14	SCHEDULE 13G/AAmendment 2	Open filing 0000929638-26-003073 Dispute this row
Lind Global Partners III LLC Common Stock, $0.01 par value	1.3	49,366	06/30/2026 Filed 2026-08-14	SCHEDULE 13G/AAmendment 2	Open filing 0000929638-26-003073 Dispute this row
EASTON JEFF Common Stock, $0.01 par value	1.4	51,866	06/30/2026 Filed 2026-08-14	SCHEDULE 13G/AAmendment 2	Open filing 0000929638-26-003073 Dispute this row
Ayrton Capital LLC Common Stock, $0.01 par value per share	2.93	111,145.00	06/30/2026 Filed 2026-08-13	SCHEDULE 13G/AAmendment 1	Open filing 0001493152-26-037652 Dispute this row
Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B Common Stock, $0.01 par value per share	2.93	111,145.00	06/30/2026 Filed 2026-08-13	SCHEDULE 13G/AAmendment 1	Open filing 0001493152-26-037652 Dispute this row
Waqas Khatri Common Stock, $0.01 par value per share	2.93	111,145.00	06/30/2026 Filed 2026-08-13	SCHEDULE 13G/AAmendment 1	Open filing 0001493152-26-037652 Dispute this row
Lind Global Fund III LP Common Stock, $0.01 par value	7.76	158,732	03/31/2026 Filed 2026-05-15	SCHEDULE 13G/AAmendment 1	Open filing 0000929638-26-001905 Dispute this row
Lind Global Partners III LLC Common Stock, $0.01 par value	7.76	158,732	03/31/2026 Filed 2026-05-15	SCHEDULE 13G/AAmendment 1	Open filing 0000929638-26-001905 Dispute this row
EASTON JEFF Common Stock, $0.01 par value	7.87	161,232	03/31/2026 Filed 2026-05-15	SCHEDULE 13G/AAmendment 1	Open filing 0000929638-26-001905 Dispute this row
Mitchell P. Kopin Common Stock, par value $0.01 per share	4.99	31,353.00	12/11/2025 Filed 2025-12-17	SCHEDULE 13G	Open filing 0001213900-25-123020 Dispute this row
Daniel B. Asher Common Stock, par value $0.01 per share	4.99	31,353.00	12/11/2025 Filed 2025-12-17	SCHEDULE 13G	Open filing 0001213900-25-123020 Dispute this row
INTRACOASTAL CAPITAL, LLC Common Stock, par value $0.01 per share	4.99	31,353.00	12/11/2025 Filed 2025-12-17	SCHEDULE 13G	Open filing 0001213900-25-123020 Dispute this row
Northstrive Fund II LP Common Stock, $0.01 par value per share	0	0.00	12/09/2025 Filed 2025-12-10	SCHEDULE 13G/AAmendment 1	Open filing 0001213900-25-120055 Dispute this row
Braeden Lichti Common Stock, $0.01 par value per share	0	0.00	12/09/2025 Filed 2025-12-10	SCHEDULE 13G/AAmendment 1	Open filing 0001213900-25-120055 Dispute this row
Braeden Lichti Common Stock, $0.01 par value per share	0	0.00	12/09/2025 Filed 2025-12-10	SCHEDULE 13G/AAmendment 1	Open filing 0001213900-25-120056 Dispute this row
Northstrive Fund II LP Common Stock, $0.01 par value per share	0	0.00	12/09/2025 Filed 2025-12-10	SCHEDULE 13G/AAmendment 1	Open filing 0001213900-25-120056 Dispute this row
Braeden Lichti Common Stock, $0.01 par value per share	5.01	29,920.00	12/03/2025 Filed 2025-12-05	SCHEDULE 13G	Open filing 0001213900-25-118884 Dispute this row
Northstrive Fund II LP Common Stock, $0.01 par value per share	4.34	25,915.00	12/03/2025 Filed 2025-12-05	SCHEDULE 13G	Open filing 0001213900-25-118884 Dispute this row
Northstrive Fund II LP Common Stock, $0.01 par value per share	4.34	25,915.00	12/03/2025 Filed 2025-12-05	SCHEDULE 13G	Open filing 0001213900-25-118848 Dispute this row
Braeden Lichti Common Stock, $0.01 par value per share	5.01	29,920.00	12/03/2025 Filed 2025-12-05	SCHEDULE 13G	Open filing 0001213900-25-118848 Dispute this row
Ayrton Capital LLC Common Stock, $0.01 par value per share	9.99	658,465.00	09/30/2025 Filed 2025-11-13	SCHEDULE 13G	Open filing 0001493152-25-022260 Dispute this row
Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B Common Stock, $0.01 par value per share	9.99	658,465.00	09/30/2025 Filed 2025-11-13	SCHEDULE 13G	Open filing 0001493152-25-022260 Dispute this row
Waqas Khatri Common Stock, $0.01 par value per share	9.99	658,465.00	09/30/2025 Filed 2025-11-13	SCHEDULE 13G	Open filing 0001493152-25-022260 Dispute this row
AdvisorShares Trust Common Stock, $0.01 par value	6.27	203,679	09/30/2025 Filed 2025-10-03	SCHEDULE 13G	Open filing 0000929638-25-003807 Dispute this row
Mitchell P. Kopin Common Stock, par value $0.01 per share	0.4	19,333.00	09/18/2025 Filed 2025-09-24	SCHEDULE 13G	Open filing 0001213900-25-091199 Dispute this row
Daniel B. Asher Common Stock, par value $0.01 per share	0.4	19,333.00	09/18/2025 Filed 2025-09-24	SCHEDULE 13G	Open filing 0001213900-25-091199 Dispute this row
Intracoastal Capital LLC Common Stock, par value $0.01 per share	0.4	19,333.00	09/18/2025 Filed 2025-09-24	SCHEDULE 13G	Open filing 0001213900-25-091199 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

1,756,294 filings read, dated 2004-06-14 to 2026-11-12: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing year	Filings read
2015	1
2016	204,322
2017	202,494
2018	202,048
2019	193,638
2020	144,184
2021	224,474
2022	40,015
2023	199,811
2024	84,357
2025	235,518
2026	19,657

Filings made before the SEC required XML are listed, not extracted.

Back to Enveric Biosciences, Inc.